Sullivan, Bruyette, Speros & Blaney’s Vertex Pharmaceuticals VRTX Stock Holding History

Sullivan, Bruyette, Speros & Blaney’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	$244K	Hold	1,134	–	–	0.01%	268
2020 Q4	$268K	Buy	1,134 +50	+5%	+$11.5K	0.01%	241
2020 Q3	$295K	Sell	1,084 -9	-0.8%	-$2.48K	0.02%	203
2020 Q2	$317K	Buy	1,093 +18	+2%	+$4.88K	0.02%	178
2020 Q1	$256K	Hold	1,075	–	–	0.02%	181
2019 Q4	$235K	Hold	1,075	–	–	0.01%	224
2019 Q3	$182K	Buy	+1,075	New	+$190K	0.01%	253

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Sullivan, Bruyette, Speros & Blaney's VRTX Position: Q1 2021 in Review

Sullivan, Bruyette, Speros & Blaney held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2021 at 1,134 shares worth $244K. The position accounts for 0.01% of the portfolio, ranked #268.

Sullivan, Bruyette, Speros & Blaney first reported a position in VRTX in Q3 2019 and has held it in 7 quarters since. The position peaked at $317K in Q2 2020. 1,000 funds tracked by Wall St. Rank hold VRTX as of Q1 2021.

Sullivan, Bruyette, Speros & Blaney held 1,134 shares of Vertex Pharmaceuticals worth $244K as of Q1 2021.
Sullivan, Bruyette, Speros & Blaney left its Vertex Pharmaceuticals share count unchanged in Q1 2021.
Vertex Pharmaceuticals made up 0.01% of Sullivan, Bruyette, Speros & Blaney's portfolio in Q1 2021, its #268 holding.
Sullivan, Bruyette, Speros & Blaney first reported a position in Vertex Pharmaceuticals in Q3 2019 and has held it in 7 quarters since.
Sullivan, Bruyette, Speros & Blaney's Vertex Pharmaceuticals position peaked at $317K in Q2 2020.
1,000 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2021.

Based on Sullivan, Bruyette, Speros & Blaney's 13F filing for Q1 2021, filed 10 May 2021.